Novartis Cosentyx Receives FDA Approval for Treatment of Children and Adolescents with Moderate to Severe Plaque Psoriasis

EAST HANOVER, N.J., June 1, 2021 /PRNewswire/ -- Novartis, a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of moderate to severe...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news